The adenosine antagonist theophylline impairs P50 auditory sensory gating in normal subjects

被引：0
作者：
Ghisolfi E.S. [1 ,2 ]
Prokopiuk A.S. [1 ]
Becker J. [3 ,4 ]
Ehlers J.A. [4 ]
Belmonte-De-Abreu P. [2 ]
Souza D.O. [1 ]
Lara D.R. [5 ,6 ]
机构：
[1] Departamento De Bioquímica, Instituto De Ciências Básicas Da Saúde, UFRGS, Porto Alegre, RS
[2] Departamento De Psiquiatria, Hospital De Clínicas De Porto Alegre, UFRGS, Porto Alegre, RS
[3] Unidade De Neurofisiologia, Universidade Luterana Do Brasil, ULBRA, Canoas, RS
[4] Departamento De Neurologia, HCPA, UFRGS, Porto Alegre, RS
[5] Departamento De Ciências Fisiológicas, Faculdade De Biociências, PUCRS, Porto Alegre, RS
[6] Faculdade De Biociências, PUC-RS, Porto Alegre, RS, 90619-900, Av. Ip. 6681 Pred. 12 A
来源：
Neuropsychopharmacology | 2002年 / 27卷 / 4期
关键词：
Adenosine; Event related potentials; P50; Purinergic system; Schizophrenia; Sensory gating; Theophylline;
D O I：
10.1016/S0893-133X(02)00337-8
中图分类号：
学科分类号：
摘要：
In the P50 suppression paradigm, when two auditory stimuli are presented 500 ms apart, the amplitude of the second response (S2), compared with the first (S1), is markedly attenuated in healthy subjects. This is an index of sensory gating. Most schizophrenic patients fail to inhibit the P50 response to the second stimulus, which is assumed to reflect an inhibitory deficit. Adenosine is a neuromodulator with mostly inhibitory activity which is released by physiological stimuli. Since this inhibitory pattern resembles the phenomenon of sensory gating, the contribution of adenosine to P50 suppression was investigated in normal volunteers after treatment with the adenosine antagonist theophylline or placebo. P50 recordings were conducted in thirteen healthy subjects at baseline and 5, 30, 60, and 90 min after oral administration of theophylline (0.66 mg/kg, maximum dose of 500 mg) or placebo in a cross-over design. Baseline results from 17 drug-treated schizophrenic patients were included for comparison. Compared with placebo, theophylline treatment significantly increased P50 ratio (S2/S1) from 0.28 ± 0.03 to 0.82 ± 0.11 at 30 min and 0.61 ± 0.07 at 60 min (mean ± SEM), which were not significantly different from the schizophrenia group (0.74 ± 0.05). The increased P50 ratio by theophylline was due to a combined decrease in S1 and increase in S2 amplitude. The impairment of P50 suppression by theophylline in normal subjects suggests a modulatory role of adenosine in sensory gating, which may be related to P50 suppression deficit in schizophrenia and is in agreement with a hypoadenosinergic model of schizophrenia. © 2002 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.
引用
收藏
页码：629 / 637
页数：8
相关论文
共 50 条
[1]  
Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., Laruelle M., From the cover: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia, Proc Natl Acad Sci USA, 97, pp. 8104-8109, (2000)
[2]  
Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R., Schizophrenia, sensory gating, and nicotinic receptors, Schizophr Bull, 24, pp. 189-202, (1998)
[3]  
Akhondzadeh S., Shasavand E., Jamilian H., Shabestari O., Kamalipour A., Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions, J Clin Pharm Ther, 25, pp. 131-137, (2000)
[4]  
Alkondon M., Pereira E.F., Albuquerque E.X., Alpha-bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices, Brain Res, 810, pp. 257-263, (1998)
[5]  
Alkondon M., Pereira E.F., Eisenberg H.M., Albuquerque E.X., Nicotinic receptor activation in human cerebral cortical interneurons: A mechanism for inhibition and disinhibition of neuronal networks, J Neurosci, 20, pp. 66-75, (2000)
[6]  
Browne R.G., Welch W.M., Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists, Science, 217, pp. 1157-1159, (1982)
[7]  
Brundege J.M., Dunwiddie T.V., Role of adenosine as a modulator of synaptic activity in the central nervous system, Adv Pharmacol, 39, pp. 353-391, (1997)
[8]  
Brunstein M.G., Belmonte-de-Abreu P., Souza D.O., Lara D.R., Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions, J Clin Pharm Ther, 26, pp. 155-156, (2001)
[9]  
Carter A.J., O'Connor W.T., Carter M.J., Ungerstedt U., Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors, J Pharmacol Exp Ther, 273, pp. 637-642, (1995)
[10]  
Curtis L., Blouin J.L., Radhakrishna U., Gehrig C., Lasseter V.K., Wolyniec P., Nestadt G., Dombroski B., Kazazian H.H., Pulver A.E., Housman D., Bertrand D., Antonarakis S.E., No evidence for linkage between schizophrenia and markers at chromosome 15q13-14, Am J Med Genet, 88, pp. 109-112, (1999)
12345